| Brian R Davis, MD | |
|
1325 W South Jordan Pkwy, Suite 103, South Jordan, UT 84095-9060 | |
| (801) 253-3080 | |
| (801) 253-0772 |
| Full Name | Brian R Davis |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 34 Years |
| Location | 1325 W South Jordan Pkwy, South Jordan, Utah |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1679583470 | NPI | - | NPPES |
| D0565 | Other | UT | MEDICAID LICENSE NUMBER |
| DH0042 | Other | UT | RRMD GROUP |
| 180043150 | Other | UT | RAILROAD MEDICARE |
| 1679583470 | Medicaid | UT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 172302-1205 (Utah) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Riverton Hospital | Riverton, UT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Davis Vision Center Associates Pllc | 0446388805 | 3 |
News Archive
The 18th Conference on Retroviruses and Opportunistic Infections is being held at the Hynes Convention Center in Boston from February 27 through March 2. Day three of this major HIV/AIDS research conference included the following selected presentations from scientists supported by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.
Fatty liver disease is contributing to an increase in liver cancer and basic scientists at The University of Texas Health Science at Houston have new insight as to why.
Alcyone Lifesciences, Inc., a leader in neural intervention systems for neurological conditions and targeted drug delivery, and DNAtrix Inc., a privately held biotechnology company and a leader in oncolytic virus therapy, have entered into an exclusive clinical collaboration. Under the agreement, DNAtrix will utilize Alcyone's MEMS Cannula (AMC) targeted delivery platform for the intratumoral delivery of DNX-2401, an oncolytic adenovirus and DNAtrix's lead product for the treatment of the most aggressive form of brain cancer, glioblastoma (GBM).
Combination checkpoint blockade before surgery (neoadjuvant therapy) produced a high response rate among patients with high-risk stage 3 melanoma, with nearly half having no sign of disease at surgery, but a high incidence of side effects caused the trial to be closed early.
Support for the new health reform law has dropped seven percentage points in the last two months, though it remains higher than when the law was first signed in March. "Forty-nine percent of Americans now disapprove of the health care reform measure, according to the poll, which was conducted July 9-12. Thirty-six percent support the law. In a May CBS News poll, 47 percent disapproved of the new laws, while 43 percent approved. While the new poll shows a recent drop in support, the numbers have still improved overall since March, when 53 percent of Americans disapproved of the new laws and 32 percent said they approved of them."
› Verified 3 days ago
| Entity Name | Davis Vision Center Associates Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689997165 PECOS PAC ID: 0446388805 Enrollment ID: O20100506000263 |
News Archive
The 18th Conference on Retroviruses and Opportunistic Infections is being held at the Hynes Convention Center in Boston from February 27 through March 2. Day three of this major HIV/AIDS research conference included the following selected presentations from scientists supported by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.
Fatty liver disease is contributing to an increase in liver cancer and basic scientists at The University of Texas Health Science at Houston have new insight as to why.
Alcyone Lifesciences, Inc., a leader in neural intervention systems for neurological conditions and targeted drug delivery, and DNAtrix Inc., a privately held biotechnology company and a leader in oncolytic virus therapy, have entered into an exclusive clinical collaboration. Under the agreement, DNAtrix will utilize Alcyone's MEMS Cannula (AMC) targeted delivery platform for the intratumoral delivery of DNX-2401, an oncolytic adenovirus and DNAtrix's lead product for the treatment of the most aggressive form of brain cancer, glioblastoma (GBM).
Combination checkpoint blockade before surgery (neoadjuvant therapy) produced a high response rate among patients with high-risk stage 3 melanoma, with nearly half having no sign of disease at surgery, but a high incidence of side effects caused the trial to be closed early.
Support for the new health reform law has dropped seven percentage points in the last two months, though it remains higher than when the law was first signed in March. "Forty-nine percent of Americans now disapprove of the health care reform measure, according to the poll, which was conducted July 9-12. Thirty-six percent support the law. In a May CBS News poll, 47 percent disapproved of the new laws, while 43 percent approved. While the new poll shows a recent drop in support, the numbers have still improved overall since March, when 53 percent of Americans disapproved of the new laws and 32 percent said they approved of them."
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Brian R Davis, MD 1325 W South Jordan Pkwy, Suite 103, South Jordan, UT 84095-9060 Ph: (801) 952-9500 | Brian R Davis, MD 1325 W South Jordan Pkwy, Suite 103, South Jordan, UT 84095-9060 Ph: (801) 253-3080 |
News Archive
The 18th Conference on Retroviruses and Opportunistic Infections is being held at the Hynes Convention Center in Boston from February 27 through March 2. Day three of this major HIV/AIDS research conference included the following selected presentations from scientists supported by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.
Fatty liver disease is contributing to an increase in liver cancer and basic scientists at The University of Texas Health Science at Houston have new insight as to why.
Alcyone Lifesciences, Inc., a leader in neural intervention systems for neurological conditions and targeted drug delivery, and DNAtrix Inc., a privately held biotechnology company and a leader in oncolytic virus therapy, have entered into an exclusive clinical collaboration. Under the agreement, DNAtrix will utilize Alcyone's MEMS Cannula (AMC) targeted delivery platform for the intratumoral delivery of DNX-2401, an oncolytic adenovirus and DNAtrix's lead product for the treatment of the most aggressive form of brain cancer, glioblastoma (GBM).
Combination checkpoint blockade before surgery (neoadjuvant therapy) produced a high response rate among patients with high-risk stage 3 melanoma, with nearly half having no sign of disease at surgery, but a high incidence of side effects caused the trial to be closed early.
Support for the new health reform law has dropped seven percentage points in the last two months, though it remains higher than when the law was first signed in March. "Forty-nine percent of Americans now disapprove of the health care reform measure, according to the poll, which was conducted July 9-12. Thirty-six percent support the law. In a May CBS News poll, 47 percent disapproved of the new laws, while 43 percent approved. While the new poll shows a recent drop in support, the numbers have still improved overall since March, when 53 percent of Americans disapproved of the new laws and 32 percent said they approved of them."
› Verified 3 days ago
Dr. Gordon Charles Jensen, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 922 Baxter Dr, Suit 110, South Jordan, UT 84095 Phone: 801-916-9099 |